Erica VanderPorten

Erica VanderPorten

UNVERIFIED PROFILE

Are you Erica VanderPorten?   Register this Author

Register author
Erica VanderPorten

Erica VanderPorten

Publications by authors named "Erica VanderPorten"

Are you Erica VanderPorten?   Register this Author

14Publications

589Reads

34Profile Views

Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).

ACS Med Chem Lett 2018 May 2;9(5):417-421. Epub 2018 Apr 2.

Department of Discovery Chemistry, Department of Biochemical and Cellular Pharmacology, Department of Drug Metabolism and Pharmacokinetics, and Department of Translational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acsmedchemlett.7b00427
Publisher Site
http://dx.doi.org/10.1021/acsmedchemlett.7b00427DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949840PMC
May 2018

Identification of Small-Molecule Noncovalent Binders Utilizing SAMDI Technology.

SLAS Discov 2017 12 5;22(10):1211-1217. Epub 2017 Jun 5.

1 Biochemical and Cellular Pharmacology Department, Genentech Inc., San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2472555217712761DOI Listing
December 2017

Label-free high-throughput assays to screen and characterize novel lactate dehydrogenase inhibitors.

Anal Biochem 2013 Oct 16;441(2):115-22. Epub 2013 Jul 16.

Biochemical and Cellular Pharmacology, Genentech, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ab.2013.07.003DOI Listing
October 2013

Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2).

Biochemistry 2010 Apr;49(14):3092-100

Biochemical Pharmacology and Early Leads, Genentech, Inc.,One DNA Way, South San Francisco, California 90480, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi901726cDOI Listing
April 2010

The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model.

Mol Cancer Ther 2009 Apr;8(4):930-9

Department of Biology, Sunesis Pharmaceuticals, Inc., 395 Oyster Point Boulevard, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0754DOI Listing
April 2009

Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors.

Bioorg Med Chem Lett 2008 Oct 29;18(19):5186-9. Epub 2008 Aug 29.

Sunesis Pharmaceuticals, Inc., 395 Oyster Point Boulevard Suite 400, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2008.08.091DOI Listing
October 2008

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.

Bioorg Med Chem Lett 2008 Oct 29;18(20):5648-52. Epub 2008 Aug 29.

Department of Biology, Sunesis Pharmaceuticals, Inc., 395 Oyster Point Boulevard Suite 400, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2008.08.095DOI Listing
October 2008